Tenon Medical (TNON) said late Monday the US Food and Drug Administration has cleared an expanded indication for its Catamaran SI Joint Fusion System for use in augmenting thoracolumbar fusion.
The Catamaran is now indicated to treat the sacroiliac joint as a stand-alone treatment or to augment a spinal fusion, Tenon said.
The shares were rising over 40% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments